Regulus Therapeutics Long Term Debt

Regulus Therapeutics (RGLS) currently reports a long-term debt of $1.4M as of March 2025. That compares with $870K in the prior-year period — up 61.4% year over year. Use the charts on this page to explore Regulus Therapeutics's long-term debt history and peer comparisons.

Regulus Therapeutics's long-term debt increased from $870K to $1.4M — a 61.4% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regulus Therapeutics reported $1.4M in long-term debt as of March 2025. That compares with $870K in the prior-year period — up 61.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regulus Therapeutics, and consider following RGLS for alerts when major investors trade the stock.

Regulus Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $1.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGLS with unrelated industries.